Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.31 |
| ▸ | GALR3 | O60755 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16320893 | 0.86 | GAA (0.40) | GAATSHRALDH1A1LMNAHSD17B10 | |
| SCHEMBL14990863 | 0.83 | TSHR (0.33) | GAATSHRALDH1A1 | |
| SCHEMBL364397 | 0.83 | ALDH1A1 (0.35) | GAATSHRALDH1A1LMNAHSD17B10 | |
| SCHEMBL27565535 | 0.80 | GAA (0.39) | GAATSHRALDH1A1LMNAHSD17B10 | |
| SCHEMBL2774042 | 0.79 | TSHR (0.31) | TSHR | |
| SCHEMBL13008707 | 0.79 | GAA (0.41) | GAATSHRALDH1A1CHRM2CHRM4 | |
| SCHEMBL21847349 | 0.79 | NAAA (0.34) | TSHRALDH1A1 | |
| SCHEMBL18704822 | 0.79 | TSHR (0.44) | TSHRALDH1A1 | |
| SCHEMBL19045354 | 0.78 | GAA (0.34) | GAA | |
| SCHEMBL8092480 | 0.77 | ATM (0.39) | TSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12291690-B2 | Ethers and esters of tertiary alkanols for use as aroma chemicals | BASF SE (DE) | 2025-05-06 | — | — | US | disclosed |
| EP-3867217-B1 | ETHERS AND ESTERS OF TERTIARY ALKANOLS FOR USE AS AROMA CHEMICALS | BASF SE (DE) | 2022-12-07 | — | — | EP | disclosed |
| EP-3867217-B1 | ETHERS AND ESTERS OF TERTIARY ALKANOLS FOR USE AS AROMA CHEMICALS | BASF SE (DE) | 2022-12-07 | — | — | EP | disclosed |
| US-20210388288-A1 | ETHERS AND ESTERS OF TERTIARY ALKANOLS FOR USE AS AROMA CHEMICALS | BASF SE (DE) | 2021-12-16 | — | — | US | disclosed |
| US-20210388288-A1 | ETHERS AND ESTERS OF TERTIARY ALKANOLS FOR USE AS AROMA CHEMICALS | BASF SE (DE) | 2021-12-16 | — | — | US | disclosed |
| CN-112867703-A | Ethers and esters of tertiary alkanols as fragrance chemicals | 巴斯夫欧洲公司 | 2021-05-28 | — | — | CN | disclosed |
| WO-2020079011-A1 | ETHERS AND ESTERS OF TERTIARY ALKANOLS FOR USE AS AROMA CHEMICALS | BASF SE (DE) | 2020-04-23 | — | — | WO | disclosed |
| EP-3640233-A1 | ETHERS AND ESTERS OF TERTIARY ALKANOLS FOR USE AS AROMA CHEMICALS | BASF SE (DE) | 2020-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210388288-A1 | ETHERS AND ESTERS OF TERTIARY ALKANOLS FOR USE AS AROMA CHEMICALS | OR51E2, ETV1, ALK | GAA 2737/4885TSHR 3071/4885ALDH1A1 71/4885 |
| US-12291690-B2 | Ethers and esters of tertiary alkanols for use as aroma chemicals | OR51E2, ETV1, ALK | GAA 2737/4885TSHR 3071/4885ALDH1A1 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.